blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3873512

EP3873512 - EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND USES THEREOF [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  30.06.2023
Database last updated on 19.07.2024
FormerRequest for examination was made
Status updated on  06.08.2021
FormerThe international publication has been made
Status updated on  02.05.2020
Most recent event   Tooltip28.10.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451 / US
For all designated states
CytomX Therapeutics, Inc.
151 Oyster Point Blvd, Suite 400
South San Francisco, CA 94080 / US
[2021/36]
Inventor(s)01 / LIU, Yimao
11 Walnut Street
Acton, MA 01720 / US
02 / HICKS, Stuart, W.
415 Massachusetts Avenue
North Andover, MA 01845 / US
03 / GUIDI, Cynthia, J.
5 Richard Way
Littleton, Massachusetts 01460 / US
04 / KOHLI, Neeraj
7 Wheaton Road
Arlington, MA 02474 / US
05 / CHITTENDEN, Thomas
24 Walker Farm Road
Sudbury, MA 01776 / US
06 / LAMBERT, John
19 Chalk Street
Cambridge, MA 02139 / US
07 / PAIDHUNGAT, Madan, M.
C/o Cytomx Therapeutics, Inc.
151 Oyster Point Blvd.
Suite 400
South San Francisco, CA 94080 / US
08 / SAGERT, Jason, Gary
C/o Cytomx Therapeutics, Inc.
151 Oyster Point Blvd.
Suite 400
South San Francisco, CA 94080 / US
09 / TIPTON, Kimberly, Ann
C/o Cytomx Therapeutics, Inc.
151 Oyster Point Blvd.
Suite 400
South San Francisco, CA 94080 / US
10 / CHAN, Chanty, Mariategue
C/o Cytomx Therapeutics, Inc.
151 Oyster Point Blvd.
Suite 400
South San Francisco, CA 94080 / US
11 / FOX, Ellaine Anne, Mariano
C/o Cytomx Therapeutics, Inc.
151 Oyster Point Blvd.
Suite 400
South San Francisco, CA 94080 / US
 [2021/36]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2021/36]Chapman, Desmond Mark
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date19876033.223.10.2019
[2021/36]
WO2019US57569
Priority number, dateUS201862751530P26.10.2018         Original published format: US 201862751530 P
US201962824539P27.03.2019         Original published format: US 201962824539 P
US201962846297P10.05.2019         Original published format: US 201962846297 P
[2021/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020086665
Date:30.04.2020
Language:EN
[2020/18]
Type: A1 Application with search report 
No.:EP3873512
Date:08.09.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 30.04.2020 takes the place of the publication of the European patent application.
[2021/36]
Search report(s)International search report - published on:US30.04.2020
(Supplementary) European search report - dispatched on:EP26.10.2022
ClassificationIPC:A61K39/00, A61K39/395, C07K16/28, C07K16/18, A61P35/00
[2021/36]
CPC:
A61P35/00 (EP,KR,US); C07K16/30 (EP,KR,US); A61K47/6801 (KR);
A61K47/68033 (EP,US); A61K47/68035 (EP,US); A61K47/6817 (KR);
A61K47/6849 (EP); A61K47/6851 (EP); A61K47/6857 (EP);
A61K47/6889 (KR,US); A61K2039/505 (EP,KR,US); C07K2317/24 (EP);
C07K2317/30 (EP); C07K2317/33 (EP); C07K2317/565 (KR);
C07K2317/70 (EP); C07K2317/92 (EP,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/36]
TitleGerman:EPCAM-ANTIKÖRPER, AKTIVIERBARE ANTIKÖRPER UND IMMUNOKONJUGATE UND VERWENDUNGEN DAVON[2021/36]
English:EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND USES THEREOF[2021/36]
French:ANTICORPS EPCAM, ANTICORPS ACTIVABLES, ET IMMUNOCONJUGUÉS, ET LEURS UTILISATIONS[2021/36]
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase21.05.2021National basic fee paid 
21.05.2021Search fee paid 
21.05.2021Designation fee(s) paid 
21.05.2021Examination fee paid 
Examination procedure21.05.2021Examination requested  [2021/36]
25.05.2023Amendment by applicant (claims and/or description)
04.07.2023Despatch of a communication from the examining division (Time limit: M02)
07.09.2023Reply to a communication from the examining division
Divisional application(s)EP21203506.7   Application refused  : 31.03.2022
Fees paidRenewal fee
27.10.2021Renewal fee patent year 03
27.10.2022Renewal fee patent year 04
27.10.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2010115630  (FAULSTICH HEINZ [DE], et al);
 [A]WO2012112687  (IMMUNOGEN INC [US], et al);
 [T]WO2016145349  (VIVENTIA BIO INC [CA], et al)
International search[A]US2010189651  (STAGLIANO NANCY E [US], et al);
 [A]US2016024207  (HARVEY BARRETT R [US], et al);
 [A]WO2017021540  (AGENCY SCIENCE TECH & RES [SG], et al);
 [A]US2018171012  (SONODA HIROYUKI [JP], et al)
by applicantUS5208020
 US5225539
 US5585089
 WO9711971
 WO9823289
 US6277375
 US2002147311
 US6716821
 US6913748
 US2005169933
 US7083784
 US7217797
 US2007148167
 US2007148164
 WO2007106585
 US7276497
 US2008050310
 WO2009016516
 WO2009025846
 WO2009058492
 US7538195
 US2009274713
 US7666817
 WO2010033279
 WO2010043880
 US2010129314
 WO2010081173
 WO2010091150
 WO2010115630
 WO2011130616
 US8088376
 WO2012112708
 WO2012112687
 WO2012128868
 US8426402
 US8563269
 WO2013177481
 WO2014026136
 US8765740
 US2016082114
 US9353127
 US9381256
 WO2016179285
 US2017014522
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.